BioMarin Pharmaceutical vs Sarepta Therapeutics
BMRN and SRPT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BMRN and SRPT compare
BioMarin Pharmaceutical is the larger company, worth 6.5 times as much as Sarepta Therapeutics ($11.1B against $1.7B).
BioMarin Pharmaceutical grew revenue faster over the last twelve months (11.2% versus −18.9% for Sarepta Therapeutics).
BioMarin Pharmaceutical keeps more of each dollar of sales as profit, with a net margin of 2.1% compared with −5.9% at Sarepta Therapeutics.
Sarepta Therapeutics scores higher on the StockData Score (11 against 8 for BioMarin Pharmaceutical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BMRN | SRPT |
|---|---|---|
| Size and price | ||
| Market cap | $11.1B | $1.7B |
| Share price | $57.23 | $16.07 |
| Change, 1 year | 3.5% | −10.7% |
| Change, 5 years | −37.4% | −79.9% |
| Beta (5Y) | 0.59 | 0.99 |
| Employees | 3,221 | 835 |
| StockData Score | ||
| Total score | 8 | 11 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 3 (better) | 1 |
| Performance score | 2 | 3 (better) |
| Health score | 2 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 151× | – |
| P/S | 3.3× | 0.9× (better) |
| P/B | 1.8× | 1.1× (better) |
| EV/EBITDA | 47.6× | – |
| P/FCF | 15.0× | 9.6× (better) |
| PEG | 4.44 | – |
| FCF yield | 6.7% | 10.4% (better) |
| Fair value | $30.00 | $104.78 |
| Margin of safety | −90.8% | 84.7% (better) |
| Growth | ||
| Revenue growth (TTM) | 11.2% (better) | −18.9% |
| Revenue growth, 5Y average | 11.6% | 32.4% (better) |
| Net income growth (TTM) | −88.9% | – |
| EPS growth (TTM) | −88.7% | – |
| EPS growth, 5Y average | −16.7% | – |
| Profitability | ||
| Gross margin | 76.1% | – |
| Operating margin | 4.4% (better) | −2.5% |
| Net margin | 2.1% (better) | −5.9% |
| FCF margin | 21.7% (better) | 9.0% |
| Return on equity | 1.2% (better) | −7.6% |
| Return on invested capital | 1.0% (better) | −5.3% |
| Financial health | ||
| Debt / equity | 0.66 | 0.10 (better) |
| Net debt / EBITDA | 10.96 | – |
| Interest coverage | 2.0× | – |
| Current ratio | 2.39 | 3.46 (better) |
| Altman Z-score | 1.84 (better) | −0.22 |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 101% | 102% |
| Held by insiders | 0.52% | 5.9% |
| Insider net buying, 12 months | −$4.3M | −$417K (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 7.3% | 19.4% |
Go deeper
- BMRN stock overview
- BMRN income statement
- BMRN valuation and score
- SRPT stock overview
- SRPT income statement
- SRPT valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.